Skip to main content
AMPH
NASDAQ Life Sciences

Amphastar Q3 Revenue Up 8% to $207.6M; Board Adds $50M to Buyback

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$30.1
Mkt Cap
$1.177B
52W Low
$16.645
52W High
$29.52
52W Position info
81% above low
Off High info
at 52W high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

AMPH sits 81% above its 52-week low of $16.645.

Summary

Amphastar reported Q3 revenue of $207.6 million (up 8%) and GAAP EPS of $0.87, but gross margin slipped to 48.0% on IMS remediation costs and weaker pricing. The board also authorized a $50 million increase to the share buyback program.


Key Events · Earnings and Guidance · AMPH

  • Q3 Revenue Rises 8% to $207.6M

    Net revenues came in at $207.6 million versus $191.8 million a year ago, led by record BAQSIMI sales of $58.8 million (up 10%) and Primatene MIST at $31.5 million (up 9%).

  • GAAP EPS Nearly Doubles to $0.87

    GAAP net income was $37.8 million, or $0.87 per diluted share, against $17.4 million, or $0.37, a year ago; adjusted non-GAAP EPS was $1.14.

  • Gross Margin Slips to 48.0%

    Gross margin fell from 51.4% on lower average selling prices for BAQSIMI, glucagon and epinephrine multi-dose vials, plus higher IMS remediation and facility expansion costs.

  • Board Adds $50M to Buyback

    On November 4, 2026 the board authorized a $50 million increase to the share buyback program, aimed primarily at offsetting dilution from equity compensation.


Analysis · AMPH · Life Sciences

Top-line growth of 8% and a near-doubling of GAAP net income to $37.8 million look strong, but the quality is mixed: gross margin fell to 48.0% from 51.4% as IMS remediation costs and lower pricing on BAQSIMI, glucagon and epinephrine ate into profitability. The bigger surprise is the board's $50 million buyback increase on November 4, which management frames as offsetting equity-compensation dilution — a real capital-return decision layered onto an earnings release. With the stock near its 52-week high, the buyback authorization supports the shares, while margin compression and ongoing FDA warning-letter remediation at IMS remain the swing factors for the next several quarters.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AMPH was trading at $30.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $16.65 to $29.52. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AMPH - Latest Insights

AMPH
Nov 05, 2026, 4:40 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $30.10
Real-time Price: $28.24 info
Change: -$1.86 (-6%) info
Market Cap: $1.204B info
AMPH
Nov 05, 2026, 4:10 PM EST
Source: PR Newswire
Importance Score:
7
Price at Filing: $27.66
Real-time Price: $28.24 info
Change: +$0.580 (+2%) info
Market Cap: $1.204B info
AMPH
Aug 06, 2026, 4:50 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $20.35
Real-time Price: $28.24 info
Change: +$7.89 (+39%) info
Market Cap: $1.204B info
AMPH
Aug 06, 2026, 4:05 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $20.35
Real-time Price: $28.24 info
Change: +$7.89 (+39%) info
Market Cap: $1.204B info
AMPH
Jul 13, 2026, 7:20 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $18.72
Real-time Price: $28.24 info
Change: +$9.52 (+51%) info
Market Cap: $1.204B info